Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma

Matthew S Davids; Gottfried von Keudell; Craig A Portell; Jonathon B Cohen; David C Fisher; Francine Foss; Andrew W Roberts; John F Seymour; Rod A Humerickhouse; Constantine S Tam

Journal article

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma

Matthew S Davids, Gottfried von Keudell, Craig A Portell, Jonathon B Cohen, David C Fisher, Francine Foss, Andrew W Roberts, John F Seymour, Rod A Humerickhouse, Constantine S Tam

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018

DOI: 10.1200/JCO.18.00359

University of Melbourne Researchers

Constantine Tam Author Medicine - St Vincent's Hospital

John Seymour Author Medicine - St Vincent's Hospital

Andrew Roberts Author

Grants

Funding Acknowledgements

Venetoclax is being developed in collaboration between AbbVie and Genentech-Roche. AbbVie, Genentech-Roche, and Janssen Pharmaceuticals provided financial support for the venetoclax clinical studies. AbbVie and Genentech-Roche were involved in the writing, review, and approval of this correspondence. Medical writing and support were provided by Ryan J. Bourgo, PhD, and Sharanya Ford, PhD, of AbbVie.